Myelodysplastic syndromes, Myelodysplastic syndromes, pp.363-80, 1996. ,
DOI : 10.1007/s00282-996-0363-7
URL : https://hal.archives-ouvertes.fr/hal-00127375
« Leukemia and myelodysplastic syndromes secondary to drug, radiation, and environnemental exposure, Semin Oncol, vol.19, issue.1, pp.47-84, 1992. ,
Risk factors of myelodysplastic syndromes: a case???control study, Leukemia, vol.73, issue.11, pp.1912-1918, 2005. ,
DOI : 10.1136/oem.59.9.575
Occupational and environmental exposures and myelodysplasia: A case-control study, Leukemia Research, vol.19, issue.2, pp.127-139, 1995. ,
DOI : 10.1016/0145-2126(94)00141-V
Smoking and Myelodysplastic Syndromes, Smoking and Myelodysplastic Syndromes, pp.285-291, 2000. ,
DOI : 10.1097/00001648-200005000-00010
Smoking and alcohol intake as risk factors for myelodysplastic syndromes (MDS), Leukemia Research, vol.34, issue.1, pp.1-5, 2010. ,
DOI : 10.1016/j.leukres.2009.08.006
A case-control study of myelodysplastic syndromes among Japanese men and women, Leukemia Research, vol.20, issue.9, pp.727-731, 1996. ,
DOI : 10.1016/0145-2126(96)00042-2
Hair dye use and occupational exposure to organic solvents as risk factors for myelodysplastic syndrome, Leukemia Research, vol.23, issue.1, pp.57-62, 1999. ,
DOI : 10.1016/S0145-2126(98)00135-0
Cytogenetic and morphologic subgroups of myelodysplastic syndromes in relation to occupational and hobby exposures, Scandinavian Journal of Work, Environment & Health, vol.29, issue.5, pp.378-387, 2003. ,
DOI : 10.5271/sjweh.744
Myelodysplastic Syndromes, Myelodysplastic Syndromes, pp.1872-1885, 2009. ,
DOI : 10.1056/NEJMra0902908
Myelodysplastic syndromes: an update on molecular pathology, Clinical and Translational Oncology, vol.144, issue.10, pp.652-661, 2010. ,
DOI : 10.1007/s12094-010-0574-9
DNA methylation and gene silencing in cancer, Nature Clinical Practice Oncology, vol.249, issue.1, pp.4-11, 2005. ,
DOI : 10.1038/ncponc0354
Aberrant DNA methylation is a dominant mechanism in MDS progression to AML, Blood, vol.113, issue.6, pp.1315-1325, 2009. ,
DOI : 10.1182/blood-2008-06-163246
5q- syndrome, Current Pharmaceutical Design, vol.18, issue.22, pp.3253-3260, 1994. ,
DOI : 10.2174/1381612811209023180
The Role of the Immune System in Myelodysplasia: Implications for Therapy, Seminars in Hematology, vol.45, issue.1, pp.39-48 ,
DOI : 10.1053/j.seminhematol.2007.11.006
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes, Blood, vol.114, issue.5, pp.937-951, 2009. ,
DOI : 10.1182/blood-2009-03-209262
Proposals for the classification of the myelodysplastic syndromes, British Journal of Haematology, vol.92, issue.2, pp.189-199, 1982. ,
DOI : 10.1016/0145-2126(79)90006-7
Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients, Leukemia Research, vol.24, issue.12, pp.983-992, 2000. ,
DOI : 10.1016/S0145-2126(00)00088-6
The WHO classification of MDS does make a difference, Blood, vol.103, issue.9, pp.3265-3270, 2004. ,
DOI : 10.1182/blood-2003-06-2124
The World Health Organization (WHO) classification of the myeloid neoplasms, Blood, vol.100, issue.7, pp.2292-2302, 2002. ,
DOI : 10.1182/blood-2002-04-1199
Prognostic Factors and Life Expectancy in Myelodysplastic Syndromes Classified According to WHO Criteria: A Basis for Clinical Decision Making, Journal of Clinical Oncology, vol.23, issue.30, pp.7594-7603, 2005. ,
DOI : 10.1200/JCO.2005.01.7038
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia, Blood, vol.108, issue.2, pp.419-425, 2006. ,
DOI : 10.1182/blood-2005-10-4149
Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience, Blood, vol.111, issue.2, pp.574-582, 2008. ,
DOI : 10.1182/blood-2007-06-096370
« Management of Myelodysplastic Syndromes, Update ». Oncology, vol.22, issue.12, pp.1344-1368, 2008. ,
Erythropoietin and Granulocyte-Colony Stimulating Factor Treatment Associated With Improved Survival in Myelodysplastic Syndrome, Journal of Clinical Oncology, vol.26, issue.21, pp.3607-3613, 2008. ,
DOI : 10.1200/JCO.2007.15.4906
Efficacy of Lenalidomide in Myelodysplastic Syndromes, Efficacy of Lenalidomide in Myelodysplastic Syndromes, pp.549-557, 2005. ,
DOI : 10.1056/NEJMoa041668
Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion, Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion, pp.1456-1465, 2006. ,
DOI : 10.1056/NEJMoa061292
Antithymocyte Globulin for Treatment of the Bone Marrow Failure Associated with Myelodysplastic Syndromes, Annals of Internal Medicine, vol.137, issue.3, pp.156-163, 2002. ,
DOI : 10.7326/0003-4819-137-3-200208060-00007
Decitabine improves patient outcomes in myelodysplastic syndromes, Decitabine Improves Patients Outcomes in Myelodysplastic Syndromes, pp.1794-1803, 2006. ,
DOI : 10.1002/cncr.21792
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study, The Lancet Oncology, vol.10, issue.3, pp.223-232, 2009. ,
DOI : 10.1016/S1470-2045(09)70003-8
Hypomethylating Agents and Other Novel Strategies in Myelodysplastic Syndromes, Journal of Clinical Oncology, vol.29, issue.5, pp.516-523, 2011. ,
DOI : 10.1200/JCO.2010.31.0854
Azacitidine, Myelodysplastic Syndromes, pp.1781-1789, 2005. ,
DOI : 10.2165/00003495-200565130-00004
Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine, International Journal of Cancer, vol.35, issue.1, pp.8-13, 2008. ,
DOI : 10.1002/ijc.23607
Bioavailability of Azacitidine Subcutaneous Versus Intravenous in Patients With the Myelodysplastic Syndromes, The Journal of Clinical Pharmacology, vol.41, issue.5, pp.597-602, 2005. ,
DOI : 10.1177/0091270004271947
« Stability of azacitidine in infusion fluids », Am J Hosp Pharm, vol.41, issue.6, pp.1156-1159, 1984. ,
« Stability of Azacitidine Suspensions ». The annals of Pharmacotherapy, p.546, 2011. ,
Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B, Journal of Clinical Oncology, vol.20, issue.10, pp.2429-2440, 2002. ,
DOI : 10.1200/JCO.2002.04.117
Impact of Azacytidine on the Quality of Life of Patients With Myelodysplastic Syndrome Treated in a Randomized Phase III Trial: A Cancer and Leukemia Group B Study, Journal of Clinical Oncology, vol.20, issue.10, pp.2441-2452, 2002. ,
DOI : 10.1200/JCO.2002.04.044
Azacitidine for the treatment of lower risk myelodysplastic syndromes, Cancer, vol.15, issue.6, pp.1485-1494, 2010. ,
DOI : 10.1002/cncr.24894
Hematologic Response to Three Alternative Dosing Schedules of Azacitidine in Patients With Myelodysplastic Syndromes, Journal of Clinical Oncology, vol.27, issue.11, pp.1850-1856, 2009. ,
DOI : 10.1200/JCO.2008.17.1058
Effects of azacitidine compared with conventional care regimens in elderly (???75 years) patients with higher-risk myelodysplastic syndromes, Critical Reviews in Oncology/Hematology, vol.76, issue.3, pp.218-227, 2010. ,
DOI : 10.1016/j.critrevonc.2010.04.005
Pre-Transplant 5-Azacitidine (Vidaza®) May Improve Outcome of Allogenic Hematopoietic Cell Transplantation (HCT) in Patients with Myelodyspalstic Syndrome, MDS) ». Blood (ASH Annual Meeting Abstracts, 2006. ,
Safety and efficacy of azacitidine in myelodysplastic syndromes, Drug Design, Development and Therapy, vol.4, issue.4, pp.221-229, 2010. ,
DOI : 10.2147/DDDT.S3143
A Dose and Schedule Finding Study of Maintenance Therapy with Low-Dose 5-azacitidine (AZA) after Allogenic Hemtopoietic Stem Cell Transplantation (HSCT) for High-Risk AML or MDS, Blood (ASH Annual Meeting Abstracts, 2007. ,
« Low-Dose Azacitidine for Relapse of MDS/AML after Unrelated Donor Peripheral Blood Stem Cell Transplantation, Blood (ASH Annual Meeting Abstracts, 2007. ,
In vitro assessment of cytochrome P450 inhibition and induction potential of azacitidine, Cancer Chemotherapy and Pharmacology, vol.30, issue.1, pp.995-1000, 2010. ,
DOI : 10.1007/s00280-010-1245-9
A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Patients with Myelodysplastic Syndromes, MDS) or Acute Myelogenous Leukemia (AML) ». Blood (ASH Annual Meeting Abstracts, 2009. ,
Valproic Acid at Therapeutic Plasma Levels May Increase 5-azactidine Efficacy in High Risk Myelodysplastic Syndromes, Cancer Ther, vol.15, issue.15, pp.5002-5007, 2009. ,
A phase I/II study of vorinostat an oral histone deacétylases inhibitor, in combonation with azacitidine in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) Initial results of the phase I trial: A New York Cancer Consortium, JCO, vol.26, 2008. ,
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia, Blood, vol.112, issue.4, pp.981-989, 2008. ,
DOI : 10.1182/blood-2007-10-115873
Final Results from a Phase I Combination Study of Lenalidomide and Azacitidine in Patients with Highter-Risk Myelodysplastic Syndromes (MDS), Blood. (ASH Annual Meeting Abstracts), vol.112, 2008. ,
Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia, Cancer, vol.84, issue.7, pp.1596-1604, 2008. ,
DOI : 10.1002/cncr.23789
Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept, British Journal of Haematology, vol.100, issue.6, pp.944-947, 2010. ,
DOI : 10.1111/j.1365-2141.2009.08061.x
Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*, European Journal of Haematology, vol.26, issue.2, pp.130-138, 2010. ,
DOI : 10.1111/j.1600-0609.2010.01456.x
Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group, Annals of Hematology, vol.112, issue.Suppl 1, pp.841-850, 2010. ,
DOI : 10.1007/s00277-010-1015-0
Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study, British Journal of Cancer, vol.66, issue.1, pp.192-197, 1992. ,
DOI : 10.1038/bjc.1992.241
Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo., Journal of Clinical Oncology, vol.13, issue.9, pp.2408-2416, 1995. ,
DOI : 10.1200/JCO.1995.13.9.2408
Further Analysis of Trials With Azacitidine in Patients With Myelodysplastic Syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B, Journal of Clinical Oncology, vol.24, issue.24, pp.3895-3903, 2006. ,
DOI : 10.1200/JCO.2005.05.4346
« 5-Azacytidine and Renal Tubular Dysfunction, Blood, vol.57, issue.1, pp.182-185, 1981. ,
Maintenance Therapy with Low-Dose Azacitidine (AZA) after Allogenic Hematopoietic Stem Cell Transplantation (HSCT) for Relapsed or Refractory AML or MDS: A Dose and Schedule Finding Study, Blood (ASH Annual Meeting Abstracts, 2008. ,
Azacitidine-Associated Hyperthermia and Interstitial Pneumonitis in a Patient with Myelodysplastic Syndrome, Pharmacotherapy, vol.165, issue.2, pp.1759-1762, 2007. ,
DOI : 10.1001/jama.280.2.159
Interstitial Lung Disease Associated With Azacitidine Use, American Journal of Therapeutics, vol.19, issue.2 ,
DOI : 10.1097/MJT.0b013e3181e7a526
Azacitidine-Induced Interstitial and Alveolar Fibrosis in a Patient with Myelodysplastic Syndrome, Pharmacotherapy, vol.41, issue.2, pp.765-768, 2005. ,
DOI : 10.1002/(SICI)1097-0142(19970715)80:2<286::AID-CNCR17>3.0.CO;2-Q
Tiré du site http://groups.eortc.be/qol, 2001. ,
The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology, JNCI Journal of the National Cancer Institute, vol.85, issue.5, pp.365-376, 1993. ,
DOI : 10.1093/jnci/85.5.365
Tiré du site http://groups.eortc.be, 3ème édition, 2001. ,
Martindale: The complete drug reference-36 th Ed, pp.683-684, 2009. ,
Tiré du site www.afssaps.fr, Résumé des caractéristiques du produit, p.12, 2008. ,